The energetic and experienced team as well as their unique focus on the entrepreneur's perspective at Objective Capital Partners helped us identify and partner with this advisory group. In addition to David Crean, MD and the entire Objective Capital Team, the enormous network and personal drive of Jack Florio(Managing Partner) has allowed Symple Surgical to concentrate on executing our value drivers as we bring important microwave ablation technology to the Gastroenterology community for the effective treatment of Barrett's Esophagus and esophageal adenocarcinoma. The Grizzly™Ablation System from Symple Surgical is on course to demonstrate safety and effectiveness in a small OUS human study, stated Gary Seelhorst, MS, MBA, Chief Business Officer at Symple Surgical.
It is a real pleasure to be representing Symple Surgical led by an experienced CEO like Dan Kasprzyk on a technology platform as exciting as the Grizzly™ Ablation System which has the opportunity to change the course of how Barrett's Esophagus is treated, stated Jack Florio, managing director. There is a large pool of strategic and financial investors whom we will be approaching for partnership opportunities with Symple Surgical through the final development, approval and launch of their ablation technology.